A glimpse at Selecta Biosciences Inc.’s potential climb to old highs

In the latest session, Selecta Biosciences Inc. (NASDAQ: SELB) closed at $1.75 up 2.34% from its previous closing price of $1.71. In other words, the price has increased by $+0.0400 from its previous closing price. On the day, 1442665 shares were traded. SELB stock price reached its highest trading level at $1.8600 during the session, while it also had its lowest trading level at $1.6700.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…



For a deeper understanding of Selecta Biosciences Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.70 and its Current Ratio is at 6.70. In the meantime, Its Debt-to-Equity ratio is 0.31 whereas as Long-Term Debt/Eq ratio is at 0.24.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on June 14, 2022, Reiterated its Buy rating but revised its target price to $5 from $6 previously.

On June 06, 2022, SVB Leerink started tracking the stock assigning a Outperform rating and target price of $7.

On June 15, 2021, BTIG Research started tracking the stock assigning a Buy rating and target price of $10.BTIG Research initiated its Buy rating on June 15, 2021, with a $10 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 05 when Brunn Carsten sold 13,473 shares for $1.13 per share. The transaction valued at 15,214 led to the insider holds 786,013 shares of the business.

Johnston Lloyd P. sold 3,392 shares of SELB for $3,830 on Jan 05. The Chief Operations Officer now owns 265,515 shares after completing the transaction at $1.13 per share. On Jan 05, another insider, Kishimoto Takashi Kei, who serves as the Chief Scientific Officer of the company, sold 3,392 shares for $1.13 each. As a result, the insider received 3,830 and left with 364,316 shares of the company.

Valuation Measures:

As of this moment, Selecta’s Price-to-Earnings (P/E) ratio for their current fiscal year is 5.21. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.06 while its Price-to-Book (P/B) ratio in mrq is 3.12.

Stock Price History:

Over the past 52 weeks, SELB has reached a high of $2.73, while it has fallen to a 52-week low of $0.65. The 50-Day Moving Average of the stock is 1.3192, while the 200-Day Moving Average is calculated to be 1.4194.

Shares Statistics:

For the past three months, SELB has traded an average of 681.93K shares per day and 796.9k over the past ten days. A total of 152.85M shares are outstanding, with a floating share count of 114.59M. Insiders hold about 0.40% of the company’s shares, while institutions hold 48.80% stake in the company. Shares short for SELB as of Oct 13, 2022 were 7.8M with a Short Ratio of 5.95M, compared to 5.91M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 5.11% and a Short% of Float of 7.65%.

Earnings Estimates

There are 7 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.01 for the current quarter, with a high estimate of $0.12 and a low estimate of -$0.09, while EPS last year was -$0.16. The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.05 and low estimates of -$0.15.

Analysts are recommending an EPS of between $0.25 and $0.05 for the fiscal current year, implying an average EPS of $0.15. EPS for the following year is -$0.36, with 7 analysts recommending between -$0.06 and -$0.55.

Revenue Estimates

A total of 7 analysts believe the company’s revenue will be $25.21M this quarter.It ranges from a high estimate of $45M to a low estimate of $10.5M. As of the current estimate, Selecta Biosciences Inc.’s year-ago sales were $24.43M, an estimated increase of 3.20% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $11.68M, a decrease of -61.00% less than the figure of $3.20% in the same quarter last year. There is a high estimate of $18M for the next quarter, whereas the lowest estimate is $5.12M.

A total of 7 analysts have provided revenue estimates for SELB’s current fiscal year. The highest revenue estimate was $123.44M, while the lowest revenue estimate was $89.3M, resulting in an average revenue estimate of $110.17M. In the same quarter a year ago, actual revenue was $85.08M, up 29.50% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $46.53M in the next fiscal year. The high estimate is $85.83M and the low estimate is $9.61M. The average revenue growth estimate for next year is down -57.80% from the average revenue estimate for this year.